Everything you need to know about TMS for Migraine: FDA-Cleared Devices and What You Need to Know — how it works, what it costs, and how to find a provider who actually knows what they're doing.

Migraine is far more than a severe headache. Affecting approximately 1 billion people worldwide and 39 million Americans, migraine is a complex neurological disorder characterized by recurrent attacks of moderate to severe throbbing pain — often on one side of the head — accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Roughly one-third of migraine sufferers experience aura — visual disturbances, sensory changes, or speech difficulties that precede or accompany the headache phase.

For many patients, existing treatments are inadequate. Acute medications such as triptans and NSAIDs carry contraindications, side effects, and the risk of medication-overuse headache. Preventive medications — including beta-blockers, anticonvulsants, and CGRP monoclonal antibodies — are not universally effective and often have tolerability issues. Transcranial magnetic stimulation offers a non-pharmacological, well-tolerated option that directly targets migraine pathophysiology.

What You’ll Learn

• Why migraine is a brain-based disorder, not just a vascular headache
• The difference between single-pulse TMS (sTMS) and repetitive TMS for migraine
• Which FDA-cleared TMS devices are available for migraine treatment
• What response rates and outcomes look like from clinical trials
• Whether TMS is the right option for your migraine type

The Neurological Basis of Migraine

Migraine was historically viewed as a vascular disorder, but modern neuroscience has established it as a primary brain disorder involving neural networks, neurotransmitters, and cortical excitability.

The cortical spreading depression (CSD) hypothesis remains central to understanding migraine aura. CSD is a wave of abnormally increased neural activity followed by prolonged suppression of cortical activity that slowly propagates across the brain’s surface. This wave is thought to underlie the visual and sensory phenomena of aura, and it may also trigger the pain pathways that produce the headache phase.

The trigeminal nerve and its associated pain pathways are central to migraine pain generation. The trigeminal nerve innervates the meninges (the protective membranes surrounding the brain), and when activated, it releases inflammatory neuropeptides that cause vasodilation and pain signaling.

The thalamus serves as the relay station for trigeminal pain signals traveling to the cortex, where pain perception occurs. Dysregulation in thalamic pain circuits contributes to the allodynia (pain from normally non-painful stimuli) and photophobia that characterize migraine attacks.

FDA-Cleared TMS Devices for Migraine

In 2014, the FDA cleared the first TMS device specifically for migraine — the eNeura SpringTMS system (also known as the Springlfex or Cerelief device). This device delivers single-pulse transcranial magnetic stimulation (sTMS) and is indicated for the acute treatment of migraine with aura.

In 2023, the FDA cleared a second sTMS device — the eNeura Axon — expanding the options available to migraine patients and clinicians.

These clearances were based on clinical trials demonstrating that sTMS is both safe and effective for acute migraine treatment. Importantly, the FDA cleared sTMS specifically for migraine with aura because the clinical trials enrolled this population and showed the most robust results.

Single-Pulse vs. Repetitive TMS Protocols

There are two distinct TMS approaches to migraine treatment:

Single-pulse TMS (sTMS) delivers one or a small number of magnetic pulses per session and is designed for acute migraine treatment. Patients use the device at the onset of a migraine attack, typically delivering four to eight pulses to the occipital cortex (the back of the brain). The rationale is that sTMS may interrupt cortical spreading depression or modulate trigeminal pain pathways during an active attack.

Repetitive TMS (rTMS) delivers many pulses over a sustained period and is typically used as a preventive treatment. Protocols for migraine prevention generally involve daily sessions for two to four weeks, targeting the motor cortex or the dorsolateral prefrontal cortex. Research suggests that rTMS may reduce migraine frequency and severity by normalizing cortical excitability and modulating pain-processing networks.

A head-to-head comparison study published in Cephalalgia found that both single-pulse and repetitive TMS produced clinically meaningful reductions in migraine pain, but single-pulse TMS acted faster (within minutes) while repetitive TMS produced more sustained preventive effects over weeks.

Clinical Outcomes and Efficacy

The pivotal clinical trial supporting FDA clearance of sTMS for migraine with aura enrolled 201 patients and found that:

• 39% of patients who received active sTMS were pain-free at 2 hours compared to 22% for sham treatment
• The treatment effect was even stronger for the most severely affected patients
• sTMS also reduced nausea, photophobia, and phonophobia compared to sham

For preventive rTMS, a systematic review of multiple trials found that rTMS to the motor cortex reduces migraine frequency by approximately 2 to 3 fewer headache days per month compared to sham treatment. While not a cure, this reduction is clinically meaningful for patients who suffer from frequent attacks.

Practical Use of TMS for Migraine

The sTMS device is small and portable — roughly the size of a large electric toothbrush — and is designed for patient self-administration at home. Patients hold the device against the back of their head at the onset of a migraine attack and trigger a single pulse. The treatment takes only a few minutes per session.

Repetitive TMS for migraine prevention requires visits to a clinic or doctor’s office, with daily sessions for two to four weeks followed by maintenance sessions as needed.

Safety and Side Effects

sTMS is remarkably well-tolerated. The most common adverse event is mild transient discomfort at the stimulation site. Because the device delivers only a small number of pulses per session, cumulative side effects are minimal.

rTMS carries slightly more risk, primarily the theoretical risk of seizure induction (as with all rTMS protocols). However, the risk is very low — estimated at less than 1 in 30,000 sessions with standard protocols — and patients with seizure risk factors are screened out before treatment.

Who Is a Candidate?

TMS for migraine is most appropriate for:

• Patients with migraine with aura who want to avoid or cannot tolerate acute medications
• Patients with medication-overuse headache who need a non-pharmacological option
• Patients with contraindications to triptans (such as cardiovascular disease)
• Patients seeking to reduce reliance on preventive medications

For migraine patients who have struggled to find effective treatment, TMS represents an FDA-cleared, evidence-based option that targets the neurological roots of migraine pain without the side effect burden of medications.